GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (NAS:ABIO) » Definitions » Net-Net Working Capital

ABIO (ARCA biopharma) Net-Net Working Capital : $26.48 (As of Jun. 2024)


View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

ARCA biopharma's Net-Net Working Capital for the quarter that ended in Jun. 2024 was $26.48.

The industry rank for ARCA biopharma's Net-Net Working Capital or its related term are showing as below:

ABIO's Price-to-Net-Net-Working-Capital is not ranked
in the Biotechnology industry.
Industry Median: 4.05 vs ABIO: 0.96

ARCA biopharma Net-Net Working Capital Historical Data

The historical data trend for ARCA biopharma's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARCA biopharma Net-Net Working Capital Chart

ARCA biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.92 56.74 41.20 34.17 30.29

ARCA biopharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.90 31.03 30.29 28.41 26.48

Competitive Comparison of ARCA biopharma's Net-Net Working Capital

For the Biotechnology subindustry, ARCA biopharma's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARCA biopharma's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARCA biopharma's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where ARCA biopharma's Price-to-Net-Net-Working-Capital falls into.


;
;

ARCA biopharma Net-Net Working Capital Calculation

ARCA biopharma's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(37.431+0.75 * 0+0.5 * 0-0.841
-0-0)/1.208
=30.29

ARCA biopharma's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jun. 2024 is calculated as

Net-Net Working Capital(Q: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(33.283+0.75 * 0+0.5 * 0-1.271
-0-0)/1.209
=26.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


ARCA biopharma  (NAS:ABIO) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


ARCA biopharma Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


ARCA biopharma Business Description

Traded in Other Exchanges
N/A
Address
10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Executives
James P Flynn director 41 HARRIS CT, DANVILLE CA 94526
Funicular Funds, Lp 10 percent owner, other: See Footnote 1 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Funicular Fund, Lp other: See Footnote 1 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Jacob Ma-weaver other: See Remarks 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Christopher David Ozeroff officer: S.V.P., General Counsel 8001 ARISTA PLACE, SUITE 200, BROOMFIELD CO 80021
Robert E Conway director C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021
C. Jeffrey Dekker officer: Chief Financial Officer 10170 CHURCH RANCH WAY, WESTMINSTER CO 80021
Thomas A Keuer officer: Chief Operating Officer C/O ARCA BIOPHARMA, INC., 10170 CHURCH RANCH WAY, STE 100, WESTMINSTER CO 80021
Brian L. Selby officer: VP, Finance 11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER CO 80020
Venrock Healthcare Capital Partners Lp 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Scott D Sandell 10 percent owner
David M Mott 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Forest Baskett 10 percent owner
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202